Literature DB >> 18946644

Surgical resection versus palliative chemoradiotherapy for the management of pancreatic cancer with local venous invasion: a decision analysis.

Michael A Abramson1, Edward W Swanson, Edward E Whang.   

Abstract

BACKGROUND: Benefit from pancreaticoduodenectomy (PD) combined with superior mesenteric-portal vein (SMV-PV) resection in the management of pancreatic adenocarcinoma with local venous invasion remains controversial.
METHODS: Using formal decision analysis, we compared survival associated with PD plus SMV-PV resection when applied to patients with pancreatic adenocarcinoma with isolated local venous invasion (Group 1) versus that achieved with palliative chemoradiotherapy when applied to patients with locally advanced pancreatic cancer (Group 2). Individual studies were identified using Medline. A total of 1,324 and 709 patients were analyzed for Groups 1 and 2, respectively. Patients with distant metastases were excluded.
RESULTS: Overall decision analysis favored surgical resection (Group 1) over palliative chemoradiotherapy (Group 2). Sensitivity analyses indicated that this decision is sensitive to the perioperative mortality rate and the percentage of surgical resections with microscopic (R1) or macroscopic (R2) residual tumor at the resection margin. In contrast, sensitivity analysis revealed that the decision is not sensitive to the percentage of cases in which true venous invasion by cancer is documented histologically.
CONCLUSIONS: Surgical resection may confer a survival advantage over palliative chemoradiotherapy in select patients with pancreatic cancers with presumed local venous invasion.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18946644     DOI: 10.1007/s11605-008-0648-y

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  59 in total

Review 1.  Is pancreaticoduodenectomy with mesentericoportal venous resection safe and worthwhile?

Authors:  P Bachellier; H Nakano; P D Oussoultzoglou; J C Weber; K Boudjema; P D Wolf; D Jaeck
Journal:  Am J Surg       Date:  2001-08       Impact factor: 2.565

Review 2.  Primer on medical decision analysis: Part 1--Getting started.

Authors:  A S Detsky; G Naglie; M D Krahn; D Naimark; D A Redelmeier
Journal:  Med Decis Making       Date:  1997 Apr-Jun       Impact factor: 2.583

3.  The analysis of resectability and survival in pancreatic cancer patients with vascular invasion.

Authors:  D I Park; J K Lee; J E Kim; J G Hyun; S G Shim; K T Lee; S W Palk; J C Rhee; K W Choi; J H Lim; Y I Kim
Journal:  J Clin Gastroenterol       Date:  2001-03       Impact factor: 3.062

4.  Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma.

Authors:  R A Wolff; D B Evans; D M Gravel; R Lenzi; P W Pisters; J E Lee; N A Janjan; C Charnsangavej; J L Abbruzzese
Journal:  Clin Cancer Res       Date:  2001-08       Impact factor: 12.531

5.  Pancreaticoduodenectomy with vascular resection: margin status and survival duration.

Authors:  Jennifer F Tseng; Chandrajit P Raut; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Eddie K Abdalla; Henry F Gomez; Charlotte C Sun; Christopher H Crane; Robert A Wolff; Douglas B Evans
Journal:  J Gastrointest Surg       Date:  2004-12       Impact factor: 3.452

6.  Clinical implications of combined portal vein resection as a palliative procedure in patients undergoing pancreaticoduodenectomy for pancreatic head carcinoma.

Authors:  Kazuaki Shimada; Tsuyoshi Sano; Yoshihiro Sakamoto; Tomoo Kosuge
Journal:  Ann Surg Oncol       Date:  2006-12       Impact factor: 5.344

7.  A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282.

Authors:  Steven J Cohen; Ralph Dobelbower; Stuart Lipsitz; Paul J Catalano; Benjamin Sischy; Thomas J Smith; Daniel G Haller
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-08-01       Impact factor: 7.038

8.  Segmental resection and wedge excision of the portal or superior mesenteric vein during pancreatoduodenectomy.

Authors:  R C van Geenen; F J ten Kate; L T de Wit; T M van Gulik; H Obertop; D J Gouma
Journal:  Surgery       Date:  2001-02       Impact factor: 3.982

9.  Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.

Authors:  Caio M Rocha Lima; Mark R Green; Robert Rotche; Wilson H Miller; G Mark Jeffrey; Laura A Cisar; Adele Morganti; Nicoletta Orlando; Gabriela Gruia; Langdon L Miller
Journal:  J Clin Oncol       Date:  2004-09-15       Impact factor: 44.544

10.  Efficacy of venous reconstruction in patients with adenocarcinoma of the pancreatic head.

Authors:  Thomas J Howard; Nicholas Villanustre; Seth A Moore; John DeWitt; Julia LeBlanc; Dean Maglinte; Lee McHenry
Journal:  J Gastrointest Surg       Date:  2003-12       Impact factor: 3.267

View more
  4 in total

1.  An Evaluation of Artificial Neural Networks in Predicting Pancreatic Cancer Survival.

Authors:  Steven Walczak; Vic Velanovich
Journal:  J Gastrointest Surg       Date:  2017-08-03       Impact factor: 3.452

2.  Extended pancreatic resections and lymphadenectomy: An appraisal of the current evidence.

Authors:  Shailesh V Shrikhande; Savio G Barreto
Journal:  World J Gastrointest Surg       Date:  2010-02-27

3.  Computed tomography-based diagnostics might be insufficient in the determination of pancreatic cancer unresectability.

Authors:  Vyacheslav I Egorov; Roman V Petrov; Elena N Solodinina; Gregory G Karmazanovsky; Natalia S Starostina; Natalia A Kuruschkina
Journal:  World J Gastrointest Surg       Date:  2013-04-27

4.  Is there a role for arterial reconstruction in surgery for pancreatic cancer?

Authors:  Reena Ravikumar; David Holroyd; Giuseppe Fusai
Journal:  World J Gastrointest Surg       Date:  2013-03-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.